Parkinson’s disease - Articles - Page 28

Parkinson's disease illustration showing neurons containing alpha-synuclein

Neurology/Psychiatric

Novel MAO-B inhibitor ameliorates Parkinson’s disease symptoms in mice

March 3, 2023

Researchers from North Sichuan Medical College have reported the discovery and preclinical...

Aptinyx stumbles in phase II, halts trials, ponders alternatives

Feb. 28, 2023

By Lee Landenberger

A shortage of efficacy compared to placebo in a phase II study of treating cognitive impairment has put Aptinyx Inc. on the defensive. The company’s oral, small-molecule NMDA receptor modulator, NYX-458, was being studied in 99 patients with mild cognitive impairment or mild dementia associated with Parkinson’s disease or Lewy body dementia. Based on the results, Aptinyx has decided to stop the therapy’s development, along with closing its phase IIb study of another oral, small molecule, NYX-783, for treating post-traumatic stress disorder.

Celltrion and Liscure to co-develop microbiome-based Parkinson’s treatment

Feb. 28, 2023

By Tamra Sami

South Korean biotech peers Celltrion Healthcare Co. Ltd. and Liscure Biosciences Co. Ltd. signed a deal to co-develop microbiome-based oral live biotherapeutic products for Parkinson's disease.

Celltrion and Liscure to co-develop microbiome-based Parkinson’s treatment

Feb. 22, 2023

By Tamra Sami

South Korean biotech peers Celltrion Healthcare Co. Ltd. and Liscure Biosciences Co. Ltd. signed a deal to co-develop microbiome-based oral live biotherapeutic products for Parkinson's disease. Under the agreement, Celltrion, of Incheon, South Korea, will provide Seoul-based Liscure with research funding as well as additional payments as the project progresses. Liscure will lead discovery of the novel candidates, and Celltrion will be responsible for further clinical and regulatory development.

Neurology/Psychiatric

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Feb. 22, 2023

NRG Therapeutics Ltd. has been awarded a second US$500,000 grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to support its lead drug discovery program and the development of a novel treatment for Parkinson's disease.

Elderly woman holding illustration of brain with missing puzzle piece

Neurology/Psychiatric

Herantis cleared to advance HER-096 into clinic for Parkinson's disease

Feb. 21, 2023

Herantis Pharma plc has received approval from the Finnish Medicines Agency, Fimea, and an ethics committee for a clinical trial application (CTA) to start clinical development of HER-096 for Parkinson's disease.

Neurology/Psychiatric

Theranocure presents MRI contrast agents for use in Alzheimer's and Parkinson's diseases

Feb. 20, 2023

Theranocure Co. Ltd. has divulged gadolinium complexes targeting β-amyloid protein acting as magnetic resonance imaging (MRI) contrast agents reported to be useful for the diagnosis of Alzheimer's disease and the treatment of Parkinson's and Alzheimer's disease.

Neurology/Psychiatric

Ryne's development of RNDP-001 for Parkinson's disease supported by CIRM grant

Feb. 15, 2023

Ryne Biotechnology Inc. has been awarded a US$4 million Clinical Stage Research Program (CLIN1) grant by the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001 through IND submission in the next 12 months.

Neurology/Psychiatric

Researchers create endothelin-1-induced rat model of vascular parkinsonism

Feb. 13, 2023

Vascular parkinsonism (VP) results from one or more small strokes in the basal ganglia.

Neurology/Psychiatric

Biogen and C4 Therapeutics divulge new IRAK-4-targeting PROTACs

Feb. 2, 2023

Biogen Inc. and C4 Therapeutics Inc. have patented proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune and metabolic diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis, among others.